Irkutsk anti-plague institute death prompts quarantines and conflicting official accounts.
|Videos|August 29, 2020
Raj Bhopal Full Interview: COVID-19 Zugzwang
Author(s)Grant M. Gallagher
Bhopal’s recent article, COVID-19 Zugzwang, was published in Public Health in Practice.
Advertisement
Raj Bhopal, CBE DSc, BSc MD, MPH, MBChB, FRCP, FFPHM, is professor emeritus of public health at the University of Edinburgh, Scotland. He held the chair of Public Health in the university until his retirement in 2018.
Bhopal is also the author of Concepts of Epidemiology: Integrating the Ideas, Theories, Principles, and Methods of Epidemiology.
Bhopal’s recent article, COVID-19 zugzwang: Potential public health moves towards population immunity, was published in Public Health in Practice.
Public Health in Practice is an official journal of the Royal Society for Public Health and a sister journal of Public Health.
The article proposes a full suite of COVID-19 interventions.
It also argues, saliently, that scientific inquiry around various SARS-CoV-2 interventions has been frustrated by an unappealing mix of competing ethical priorities societies face, alongside political battles over terms like “herd immunity.”
Dr. Bhopal was also interviewed on the subject by Karan Thapar of The Wire.
The segment covers some of the same topics, but also explores new ones. It can be viewed below.
Advertisement
Related to this article
A laboratory technician at a Siberian anti-plague institute has died of pneumonia of unknown cause, prompting quarantines and contact monitoring while Russian officials stop short of confirming plague.
A study finding clesrovimab comparable to palivizumab in protecting at-risk infants in their first RSV season was extended to demonstrate clesrovimab effective and well-tolerated when administered in their second season.
Lori Handy, MD, provides guidance in these areas including presentation before rash onset, when patients should be considered for the inpatient setting, and what treatment looks like.
Jason Pogue, PharmD, BCPS, BCIDP, contextualizes preliminary data looking at this trial and other extended-spectrum beta-lactamase (ESBL) studies, which reopens the debate around carbapenem-sparing treatment options.
In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
With a significant increase in rabies exposures this year, Rodney Rohde, PhD, talks about seeking medical attention after animal interactions as well as clinical treatment when people have been bit or scratched.
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Advertisement
Advertisement